Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Hyponatremia and outcomes in patients with heart failure.

Goldsmith SR.

Heart. 2012 Dec;98(24):1761-2. doi: 10.1136/heartjnl-2012-302854. No abstract available.

PMID:
23204533
2.

AVP receptor antagonists in patients with CHF.

Kumar SK, Mather PJ.

Heart Fail Rev. 2009 Jun;14(2):83-6. doi: 10.1007/s10741-008-9107-9. Epub 2008 Sep 3. Review.

PMID:
18766439
3.

Hyponatremia in heart failure.

Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M.

Heart Fail Rev. 2009 Jun;14(2):59-63. doi: 10.1007/s10741-008-9109-7. Epub 2008 Aug 29. Review.

PMID:
18758941
4.

Hyponatremia in heart failure: concluding remarks.

Chatterjee K.

Heart Fail Rev. 2009 Jun;14(2):87-8. doi: 10.1007/s10741-008-9106-x. Epub 2008 Aug 29. No abstract available.

PMID:
18758942
5.

Introduction: Vasopressin therapy.

Whellan DJ.

Heart Fail Rev. 2009 Jun;14(2):57-8. doi: 10.1007/s10741-008-9116-8. Epub 2008 Nov 7. No abstract available.

PMID:
18989773
6.

Vasopressin and vasopressin antagonists in heart failure and hyponatremia.

Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M.

Curr Heart Fail Rep. 2008 Jun;5(2):91-6. Review.

PMID:
18765079
7.

Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.

Jao GT, Chiong JR.

Clin Cardiol. 2010 Nov;33(11):666-71. doi: 10.1002/clc.20822. Review.

8.

Treatment options for hyponatremia in heart failure.

Goldsmith SR.

Heart Fail Rev. 2009 Jun;14(2):65-73. doi: 10.1007/s10741-008-9110-1. Epub 2008 Sep 6. Review.

PMID:
18777208
9.

Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.

Cyr PL, Slawsky KA, Olchanski N, Krasa HB, Goss TF, Zimmer C, Hauptman PJ.

Am J Health Syst Pharm. 2011 Feb 15;68(4):328-33. doi: 10.2146/ajhp100217.

PMID:
21289328
10.

Hyponatremia, heart failure, and the role of tolvaptan.

O'Connell JB, Alemayehu A.

Postgrad Med. 2012 Mar;124(2):29-39. doi: 10.3810/pgm.2012.03.2534. Review.

PMID:
22437213
11.
12.

Tolvaptan for hyponatremia.

Ozkan C, Kirkpantur A, Arici M.

N Engl J Med. 2007 Mar 1;356(9):962; author reply 962-3. No abstract available.

PMID:
17338053
13.

Tolvaptan for hyponatremia.

Weise WJ, Rimmer JM, Hood VL.

N Engl J Med. 2007 Mar 1;356(9):961; author reply 962-3. No abstract available.

14.

Hyponatremia in heart failure: time for a trial.

Goldsmith SR.

J Card Fail. 2013 Jun;19(6):398-400. doi: 10.1016/j.cardfail.2013.04.003. Epub 2013 May 14. No abstract available. Erratum in: J Card Fail. 2013 Sep;19(9):663.

PMID:
23743488
15.

[Hyponatremia in heart failure: physiopathology and pharmacological approach].

Robledo GG, Cantillo DS, Comín Colet J.

Endocrinol Nutr. 2010 May;57 Suppl 2:10-4. doi: 10.1016/S1575-0922(10)70017-6. Review. Spanish.

PMID:
21130957
16.

Treatment options for hyponatremia in heart failure.

Goldsmith SR.

Congest Heart Fail. 2010 Jul;16 Suppl 1:S15-8. doi: 10.1111/j.1751-7133.2010.00164.x. Review.

17.
18.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators.

N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.

19.

Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.

Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Komai Y, Thandavarayan RA, Sukumaran V, Watanabe K.

Drug Discov Today. 2010 Oct;15(19-20):826-41. doi: 10.1016/j.drudis.2010.08.001. Epub 2010 Aug 11. Review.

PMID:
20708094
20.

[Vasopressin antagonist in hyponatremia. Rapid and simple control of serum sodium concentration].

[No authors listed]

MMW Fortschr Med. 2012 Dec 17;154(22):78-9. German. No abstract available.

PMID:
23297546

Supplemental Content

Support Center